Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin Opportunity

Rhea-AI Summary

Moleculin Biotech, Inc. (MBRX) will present at the Virtual Investor Lunch Break, featuring Chairman and CEO Walter Klemp discussing the company's drug candidates targeting tumors and viruses. The event will take place on March 28th, with a live webcast available on the company's website.

Live webcast with Walter Klemp, Chairman and Chief Executive Officer, on Thursday, March 28^th at 12:00 PM ET

HOUSTON, March 27, 2024 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced that it will present at the Virtual Investor Lunch Break: The Moleculin Opportunity event on Thursday, March 28, 2024 at 12:00 PM ET.

As part of the event, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, will provide a corporate overview, business outlook, and discuss the Moleculin opportunity.

A live video webcast of the event will be available on the Events page under the Investors section of the Company's website (moleculin.com). A webcast replay will be available two hours following the live event and will be accessible for 90 days.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of viruses, as well as cancer indications including brain tumors, pancreatic and other cancers. 

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-to-participate-in-the-virtual-investor-lunch-break-the-moleculin-opportunity-302100348.html

SOURCE Moleculin Biotech, Inc.

FAQ

When will the Virtual Investor Lunch Break event featuring Moleculin Biotech (MBRX) take place?

The event will be held on Thursday, March 28, 2024, at 12:00 PM ET.

Who will provide a corporate overview and business outlook at the event?

Walter Klemp, the Chairman and CEO of Moleculin Biotech, will provide a corporate overview and discuss the Moleculin opportunity.

Where can the live video webcast of the event be accessed?

The live video webcast will be available on the Events page under the Investors section of Moleculin Biotech's website (moleculin.com).

How long will the webcast replay be accessible?

The webcast replay will be accessible for 90 days, starting two hours after the live event.

What type of company is Moleculin Biotech (MBRX)?

Moleculin Biotech is a clinical stage pharmaceutical company with a portfolio of drug candidates targeting hard-to-treat tumors and viruses.